Abbott Laboratories (ABT)
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield
If you wonder whether Abbott Laboratories NYSE: ABT is a good buy in Q2 2025, the answer is yes. The company's management, portfolio, cash flow, capital return, and pipeline are why.
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
Here is how Abbott (ABT) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Down 9.0% in 4 Weeks, Here's Why Abbott (ABT) Looks Ripe for a Turnaround
Abbott (ABT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Abbott Laboratories: What's Behind The Q2 Earnings Slump?
ABT, which had been outperforming the healthcare cohort from the S&P 500 and the S&P 500 itself all through this year, has slumped dramatically following yesterday's Q2 earnings. While Q2 sales beat expectations, with YoY growth rising to its highest point in 3 years, earnings merely met estimates, disappointing given the company's history of bottom-line beats averaging 9%. ABT's second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin guidance was cut, despite the company facilitating 100bps of improvements in Q2.
Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT ) Q2 2025 Results Conference Call July 17, 2025 9:00 AM ET Company Participants Michael Comilla - Vice President of Investor Relations. Philip P. Boudreau - CFO & Executive VP of Finance Robert B.
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat
ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.
Abbott (ABT) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
Abbott (ABT) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.25 per share. This compares to earnings of $1.14 per share a year ago.
3 Medical Stocks to Watch as Q2 Earnings Approach: ABT, JNJ, NVS
The broader market's historic rebound may make it necessary to consider some defensive positions in the portfolio, and these medical stocks fit the bill ahead of their Q2 reports.
Sell ABT Stock Ahead Of Its Q2 Earnings?
Abbott Laboratories (NYSE:ABT) is scheduled to announce its second-quarter earnings on Thursday, July 17, 2025. For traders who focus on events, examining the historical reactions of the stock to earnings announcements can offer useful insights.
Countdown to Abbott (ABT) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Abbott (ABT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
